Perceptive Advisors Adjusts Lyra Therapeutics Stake

Ticker: LYRA · Form: SC 13D/A · Filed: Dec 16, 2024 · CIK: 1327273

Sentiment: neutral

Topics: ownership-change, sec-filing, activist-investor

Related Tickers: LYRA

TL;DR

Perceptive Advisors filed an amendment to their Lyra Therapeutics stake. Watch this space.

AI Summary

Perceptive Advisors LLC, along with its affiliates Perceptive Life Sciences Master Fund, Ltd. and Perceptive LS (A), LLC, has amended its Schedule 13D filing regarding Lyra Therapeutics, Inc. The filing, dated December 16, 2024, indicates a change in beneficial ownership. Joseph Edelman is also listed as a group member.

Why It Matters

Changes in beneficial ownership filings like this can signal shifts in investor sentiment or strategy, potentially impacting Lyra Therapeutics' stock price.

Risk Assessment

Risk Level: medium — Schedule 13D filings often involve significant investors, and changes can indicate strategic moves that may affect stock volatility.

Key Players & Entities

FAQ

What is the primary purpose of this SC 13D/A filing?

This filing is an amendment to a previous Schedule 13D, indicating a change in the beneficial ownership of Lyra Therapeutics, Inc. by Perceptive Advisors LLC and its affiliates.

Who are the main entities involved in this filing?

The main entities are Lyra Therapeutics, Inc. (the issuer), Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd., Perceptive LS (A), LLC, and Joseph Edelman.

When was this amendment filed?

This amendment was filed on December 16, 2024.

What is Lyra Therapeutics, Inc.'s industry?

Lyra Therapeutics, Inc. is in the Surgical & Medical Instruments & Apparatus industry, with SIC code 3841.

What is the business address of Lyra Therapeutics, Inc.?

The business address of Lyra Therapeutics, Inc. is 480 Arsenal Way, Watertown, MA 02472.

Filing Stats: 1,090 words · 4 min read · ~4 pages · Grade level 8.4 · Accepted 2024-12-16 21:02:59

Key Financial Figures

Filing Documents

of the Schedule 13D is amended and supplemented as followed

Item 4 of the Schedule 13D is amended and supplemented as followed: On December 12, 2024, each of Konstantin Poukalov and Michael Altman, Managing Directors at Perceptive Advisors, resigned as directors of the Issuer. The Reporting Persons continuously review their investment in the Issuer and, depending on various factors and subject to compliance with applicable securities laws and regulatory requirements, may dispose or distribute some or a significant amount of their Common Stock or such other securities as it or he owns or may subsequently acquire depending on various factors, including but not limited to, the price of the shares, the terms and conditions of the transaction and prevailing market conditions, as well as the liquidity and diversification objectives. Except as indicated herein, no Reporting Person, as a stockholder of the Issuer, has any plans or proposals that relates or would result in any of the transactions or other matters specified in clauses (a) though (j) of Item 4 of Schedule 13D. Each Reporting Person may, at any time and from time to time, review or reconsider its or his position and/or change its or his purpose and/or formulate plans or proposals with respect thereto.

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: December 16, 2024 PERCEPTIVE ADVISORS LLC By: /s/ Joseph Edelman Name: Joseph Edelman Title: Managing Member /s/ Joseph Edelman JOSEPH EDELMAN PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD. By: Perceptive Advisors LLC By: /s/ Joseph Edelman Name: Joseph Edelman Title: Managing Member PERCEPTIVE LS (A), LLC By: Perceptive LS GP, LLC By: /s/ Joseph Edelman Name: Joseph Edelman Title: Member

View Full Filing

View this SC 13D/A filing on SEC EDGAR

View on Read The Filing